戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nical small molecules are low-potency and/or multitargeted.
2  suggest that enoxolone's cellular action is multitargeted.
3                  We previously described the multitargeted 6-substituted pyrrolo[3,2-d]pyrimidine ant
4 his non-ATP competitive kinase inhibitor has multitargeted activity, promoting mitotic arrest and apo
5 NF-kappaB activation and their regulation by multitargeted agents in contrast to monotargeted agents,
6                                              Multitargeted agents provide tumor selectivity with redu
7                                        These multitargeted agents represent an exciting new structura
8 ghlight the potential of specific and potent multitargeted amino acid combinations for the treatment
9 assigned to receive for 24 months either the multitargeted and FLT3-kinase inhibitor sorafenib (n = 4
10                                         Both multitargeted and highly selective kinase inhibitors are
11 22584 (PTK/ZK; vatalanib), an orally active, multitargeted angiogenesis inhibitor, has shown tolerabi
12 ation of more than one bioactive moiety in a multitargeted anticancer agent may result in synergistic
13 tive flavonol ligands with the aim to obtain multitargeted anticancer agents.
14  is important for development of efficacious multitargeted anticancer drugs.
15 implications for improving immunotherapy and multitargeted anticancer therapies.
16                                              Multitargeted antifolate (MTA) is an investigational age
17 9 colon carcinoma cells was decreased by the multitargeted antifolate (MTA), LY231514.
18 cal isosteric C8-N9 bridged analogues of the multitargeted antifolate LY231514 were synthesized as in
19                              Pemetrexed is a multitargeted antifolate with manageable toxicity and ha
20 ill potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of
21 n metastatic prostate cancer will comprise a multitargeted approach aimed at both the tumor cell and
22            A more direct means by which this multitargeted approach can be achieved is by identifying
23                      Here, we investigated a multitargeted approach combining exopolysaccharide (EPS)
24 everal pro-permeability proteins providing a multitargeted approach in RVO.
25                                            A multitargeted approach involving selective local antiang
26  which we are moving from a single- toward a multitargeted approach.
27 eview, we have endeavored to showcase how a "multitargeted" approach to drug design has led to new fa
28 volved in epileptogenesis, it is likely that multitargeted approaches are required for epilepsy preve
29 esponse supports the concept of combination, multitargeted approaches rather than traditional chemoth
30                       Our data indicate that multitargeted combinatorial therapies targeting tumor ce
31                                              Multitargeted complexes which have been designed to targ
32                                         The "multitargeted" complexes described herein not only targe
33                                BMS-794833, a multitargeted compound, was identified as a potent inhib
34        Herein we report on a novel series of multitargeted compounds obtained by linking together gal
35 is, and therapeutic effects of the family of multitargeted compounds that simultaneously disrupt func
36           Overall, we provide a strategy for multitargeted degradation of IKZF2 and CK1alpha to enhan
37                                   We develop multitargeted degraders to answer fundamental questions
38                                   Therefore, multitargeted disruption of the beta-catenin-TCF7L2-JMJD
39 peutic benefits are likely attributed to its multitargeted effects on cerebrovascular patency and int
40 n to the selective FGFR inhibitor BGJ398 and multitargeted FGFR inhibitor ponatinib.
41      Our results indicate that a complex and multitargeted hsa-miRNA response occurs during CMV repli
42 les are brain-penetrant and exhibit balanced multitargeted in vitro activity in the low muM range.
43                                              Multitargeted inhibition and selective tumor transport w
44 nt and selective Bcr-Abl inhibition and with multitargeted inhibition of Bcr-Abl and Src family kinas
45  then metronomic chemotherapy, overlaid with multitargeted inhibition of PDGFR and VEGFR, gave comple
46 we describe MK-2461, a novel ATP-competitive multitargeted inhibitor of activated c-Met.
47 aling how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.
48 antification, as no blank matrix exists, the multitargeted internal calibration (MTIC) is an attracti
49 thogenesis that may benefit from coordinated multitargeted interventions.
50 emia (T-ALL) samples and pave the way toward multitargeted JAK1 and JAK3 therapy in T-ALL.
51 that takes advantage of a well-characterized multitargeted kinase inhibitor describes a nongenetic ap
52 ted to determine whether the addition of the multitargeted kinase inhibitor midostaurin to intensive
53                          The addition of the multitargeted kinase inhibitor midostaurin to standard c
54                  Dasatinib is a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family
55 ne kinase inhibitors, including dasatinib (a multitargeted kinase inhibitor of BCR-ABL and Src family
56                                Recently, the multitargeted kinase inhibitor sorafenib was shown to be
57 iruses, all of which can be amplified by the multitargeted kinase inhibitor sunitinib.
58                           KW-2449 is a novel multitargeted kinase inhibitor that induces cytotoxicity
59 b is an orally bioavailable, small molecule, multitargeted kinase inhibitor that inhibits VEGF recept
60 hether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patient
61                               Dasatinib is a multitargeted kinase inhibitor that was recently approve
62 tion of a fluorine-18 analog of dasatinib, a multitargeted kinase inhibitor, are reported.
63                 The efficacy of sorafenib, a multitargeted kinase inhibitor, in melanoma is still und
64             Our approach is based on using a multitargeted kinase inhibitor, SM1-71, as a tool compou
65 lled kinome regularization (KiR) to identify multitargeted kinase inhibitors (KIs) that abrogate CRPC
66 SRC inhibitors, dasatinib and bosutinib, are multitargeted kinase inhibitors.
67 ictions and provide evidence for the role of multitargeted KIs as chemosensitizers for late-stage, me
68 4503 alone is capable of regressing AML by a multitargeted mechanism and that the addition of bevaciz
69 ective in preventing obesity through various multitargeted mechanisms of weight loss.
70                                              Multitargeted methodologies represent a major step towar
71             This work provides evidence that multitargeted METTL may have stronger inhibition of HCC
72  and complementary approach is the design of multitargeted modulators simultaneously addressing multi
73 itable as a scaffold for the design of novel multitargeted molecules.
74                     In this Perspective, the multitargeted opioid ligand strategy for the discovery o
75 inase inhibitors (TKIs), even when these are multitargeted or applied in combination.
76                Here we report that BEZ235, a multitargeted pan-PI3K/dual-mTOR inhibitor, potently kil
77         Of the 11 eyes subjected to PPV, the multitargeted PCR results for tuberculosis were positive
78                  Consequently, it seems that multitargeted photoimmunotherapy should also be useful a
79 s hold important implications for the use of multitargeted PI3K inhibitors in the treatment of hemato
80     Vitreous fluid samples were subjected to multitargeted polymerase chain reaction (PCR) for a M. t
81  agents, which can be explained by potential multitargeted properties.
82                                 We performed multitargeted proteomics on both sample sets to identify
83 ip studies that led to the identification of multitargeted prototypes with activities as MT-stabilizi
84 (hTopos) and histone deacetylases (HDACs) by multitargeted quinoline-bridged hydroxamic acid derivati
85 bination of oral sunitinib, a small molecule multitargeted receptor tyrosine kinase (RTK) inhibitor,
86                               Sunitinib is a multitargeted receptor tyrosine kinase inhibitor approve
87                        Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor of the
88                                   SU11248, a multitargeted receptor tyrosine kinase inhibitor of VEGF
89  with solid malignancies were treated with a multitargeted receptor tyrosine kinase inhibitor resulti
90                                   ABT-869 (a multitargeted receptor tyrosine kinase inhibitor) inhibi
91                            Sunitinib (ST), a multitargeted receptor tyrosine kinase inhibitor, has be
92  with solid malignancies were treated with a multitargeted receptor tyrosine kinase inhibitor, result
93 show that targeting neovascularization via a multitargeted receptor tyrosine kinase inhibitor, suniti
94 or sequential administration of sunitinib, a multitargeted receptor tyrosine kinase inhibitor.
95                                 Effects of 4 multitargeted receptor tyrosine kinase inhibitors on reg
96 or 8 and 90 revealed that both compounds are multitargeted receptor tyrosine kinase inhibitors with l
97 type 1 infection and no cirrhosis, a 12-week multitargeted regimen of ABT-450/r-ombitasvir and dasabu
98                           Treatment with the multitargeted regimen of ombitasvir-ABT-450/r and dasabu
99                               RNA targets of multitargeted RNA-binding proteins (RBPs) can be studied
100                                 SU11657 is a multitargeted selective inhibitor of class III/V recepto
101 ood test, the fecal immunochemical test, the multitargeted stool DNA test, and the methylated SEPT9 D
102 rylimidazoles provide tools to explore novel multitargeted strategies for AD and other neurodegenerat
103                                            A multitargeted strategy to treat the consequences of isch
104                                            A multitargeted therapeutic approach using a bile acid seq
105  should encourage further development toward multitargeted therapeutic intervention in HDBC.
106   In this context, the development of single multitargeted therapeutics directed against two or more
107  we report a novel strategy in the design of multitargeted therapeutics for AD through dual inhibitio
108  aiming at the development of microRNA-based multitargeted therapeutics for AD.
109 y represent a novel target in the search for multitargeted therapies based on the HSP90 chaperone sys
110          This has spurred the development of multitargeted therapies, including small molecules that
111 with HCV genotype 1 infection and cirrhosis, multitargeted therapy with the use of three new antivira
112 images from a phase II study of sunitinib, a multitargeted TKI.
113                      Rational development of multitargeted TKIs for prostate cancer requires improved
114 ew process for ICIs, VEGF(R) inhibitors, and multitargeted TKIs, and 159 reports were selected for in
115 ost combinations with VEGF(R) inhibitors and multitargeted TKIs, exercising caution is recommended.
116               Our work supports the value of multitargeted tool compounds with well-validated polypha
117 targeted therapies rather than non-specific, multitargeted treatments.
118                                              Multitargeted tyrosine kinase inhibition has recently sh
119                                          The multitargeted tyrosine kinase inhibitor (TKI) cabozantin
120 n HIF-2alpha inhibitor in combination with a multitargeted tyrosine kinase inhibitor as a treatment o
121 trial combining anti-PD1 immunotherapy and a multitargeted tyrosine kinase inhibitor cabozantinib.
122                SU11248 is an oral, selective multitargeted tyrosine kinase inhibitor currently in Pha
123 We conducted a phase II trial evaluating the multitargeted tyrosine kinase inhibitor lenvatinib in pa
124 ffect of mTOR inhibitor temsirolimus and the multitargeted tyrosine kinase inhibitor lenvatinib was v
125  FGFR2-mutated oral SCC who responded to the multitargeted tyrosine kinase inhibitor pazopanib.
126                                          The multitargeted tyrosine kinase inhibitor sorafenib is use
127 e therapy using FLT3 inhibitors, such as the multitargeted tyrosine kinase inhibitor sorafenib, impro
128                                    The novel multitargeted tyrosine kinase inhibitor sunitinib is use
129                                              Multitargeted tyrosine kinase inhibitor sunitinib reduce
130               Nilotinib, a recently approved multitargeted tyrosine kinase inhibitor targeting the BC
131 lity of sunitinib malate (SU11248), an oral, multitargeted tyrosine kinase inhibitor that blocks the
132 ial growth factor receptor 2, c-MET, and RET multitargeted tyrosine kinase inhibitor that has antiang
133           Sunitinib is a clinically approved multitargeted tyrosine kinase inhibitor that inhibits va
134                        Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits va
135                  SU11657, a selective, oral, multitargeted tyrosine kinase inhibitor that targets FLT
136                  Dasatinib (BMS-354825) is a multitargeted tyrosine kinase inhibitor that targets onc
137               In this study, we discovered a multitargeted tyrosine kinase inhibitor, compound 15a, w
138                                 Pazopanib, a multitargeted tyrosine kinase inhibitor, has recently be
139 lity and anticancer efficacy of sunitinib, a multitargeted tyrosine kinase inhibitor, in patients wit
140                  Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, which has shown
141 staurin (PKC412; N-benzoylstaurosporin) is a multitargeted tyrosine kinase inhibitor, with demonstrat
142 ated whether a multimodal strategy combining multitargeted tyrosine kinase inhibitors (MTKIs) and mic
143                                              Multitargeted tyrosine kinase inhibitors (TKIs) of the v
144 h factor (receptor) [VEGF(R)] inhibitors, or multitargeted tyrosine kinase inhibitors (TKIs).
145                                          The multitargeted tyrosine kinase inhibitors Crizotinib and
146 neuregulin, whereas the off-target effect of multitargeted tyrosine kinase inhibitors may be mediated
147 n HIF-2alpha inhibitor, with cabozantinib, a multitargeted tyrosine-kinase inhibitor of VEGFR, c-MET,
148                           Zanzalintinib is a multitargeted tyrosine-kinase inhibitor that, when combi
149                                 Sunitinib, a multitargeted tyrosine-kinase inhibitor, which is approv

 
Page Top